Publication Name	World Journal of Gastrointestinal Pharmacology and Therapeutics
Manuscript ID	33844
Country	United States

Received	2017-03-07 09:01
Peer-Review Started	2017-03-10 10:30
First Decision by Editorial Office Director
Return for Revision	2017-03-29 15:26
Revised	2017-04-07 02:57
Publication Fee Transferred
Second Decision by Editor	2017-04-18 16:40
Second Decision by Editor-in-Chief	2017-04-19 01:19
Final Decision by Editorial Office Director	2017-04-24 10:52
Articles in Press	2017-04-24 10:52
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-04-28 10:03
Publish the Manuscript Online	2017-05-04 08:16

ISSN	2150-5349 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Combination therapy for inflammatory bowel disease
Manuscript Source	Invited Manuscript
All Author List	Keith S Sultan, Joshua C Berkowitz and Sundas Khan
Funding Agency and Grant Number
Corresponding Author	Keith S Sultan, MD, Assistant Professor of Medicine, Department of Medicine, Division of Gastroenterology, Hofstra Northwell School of Medicine, 300 Community Dr., Manhasset, NY 11030, United States. ksultan@northwell.edu
Key Words	Crohn’s disease; Adalimumab; Vedolizumab; Ulcerative colitis; Infliximab; Inflammatory bowel disease; Methotrexate; Azathioprine
Core Tip	The benefits of combination therapy (CT) with infliximab and azathioprine likely outweigh its risks in treatment naïve patients with moderate to severe Crohn’s disease and ulcerative colitis. A similar benefit in patients already failing biologics or immunomodulators is not as well defined. There is a lack of strong prospective evidence demonstrating a benefit for CT with adalimumab and an immunomodulator. While expert guidelines emphasize the use of CT, its use should be preceded by a careful weighing of the risks and benefits by the physician and patient, especially in scenarios where the strongest evidence for CT may not directly apply.
Publish Date	2017-05-04 08:16
Citation	Sultan KS, Berkowitz JC, Khan S. Combination therapy for inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2017; 8(2): 103-113
URL	http://www.wjgnet.com/2150-5349/full/v8/i2/103.htm
DOI	http://dx.doi.org/10.4292/wjgpt.v8.i2.103

Full Article (PDF)	WJGPT-8-103.pdf
Full Article (Word)	WJGPT-8-103.doc
Manuscript File	33844-Review.docx
Answering Reviewers	33844-Answering reviewers.pdf
Audio Core Tip	33844-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	33844-Conflict-of-interest statement.pdf
Copyright License Agreement	33844-Copyright assignment.pdf
Supplementary Material	Supplementary_Material_20170307011750.docx
Peer-review Report	33844-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	33844-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	33844-Scientific misconduct check.pdf
Scientific Editor Work List	33844-Scientific editor work list.pdf